{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:25Z","timestamp":1791921505102,"version":"4.3.4"},"reference-count":199,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy of Craiova, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Asthma represents a heterogeneous disorder characterized by a dynamic balance between pro-inflammatory and anti-inflammatory forces, with allergic sensitization contributing substantially to airway hyperresponsiveness and remodeling. Central to its pathogenesis are cytokines such as IL-4, IL-5, IL-13, IL-17, and IL-33, which drive recruitment of eosinophils, neutrophils, and other effector cells, thereby precipitating episodic exacerbations in response to viral and environmental triggers. Conventional biomarkers, including blood and sputum eosinophil counts, IgE levels, and fractional exhaled nitric oxide, facilitate phenotypic classification and guide the emerging biologic era. Monoclonal antibodies targeting IgE (omalizumab) and IL-5 (mepolizumab, benralizumab, reslizumab, depemokimab) have demonstrated the ability to reduce exacerbation frequency and improve lung function, with newer agents such as depemokimab offering extended dosing intervals. Itepekimab, an anti-IL-33 antibody, effectively engages its target and mitigates tissue eosinophilia, while CM310-stapokibart, tralokinumab, and lebrikizumab inhibit IL-4\/IL-13 signaling with variable efficacy depending on patient biomarkers. Comparative analyses of these biologics, encompassing affinity, dosing regimens, and trial outcomes, underscore the imperative of personalized therapy to optimize disease control in severe asthma.<\/jats:p>","DOI":"10.3390\/ph18071021","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:38:27Z","timestamp":1752140307000},"page":"1021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications"],"prefix":"10.3390","volume":"18","author":[{"given":"Renata Maria","family":"V\u0103ru\u021b","sequence":"first","affiliation":[{"name":"Research Methodology Department, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6065-2782","authenticated-orcid":false,"given":"Dop","family":"Dalia","sequence":"additional","affiliation":[{"name":"Department of Mother and Baby, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Radivojevic","sequence":"additional","affiliation":[{"name":"Research Methodology Department, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Maria","family":"Trasca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George-Alin","family":"Stoica","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niculescu Stefan","family":"Adrian","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niculescu Elena","family":"Carmen","sequence":"additional","affiliation":[{"name":"Department of Mother and Baby, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Elena","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Mother and Baby, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref_1","unstructured":"Collaborators GBDS (2021). Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol., 20, 795\u2013820."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","article-title":"Improving lung health in low-income and middle-income countries: From challenges to solutions","volume":"397","author":"Meghji","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 Gina report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: Central mediator of allergic asthma","volume":"282","author":"Luyimbazi","year":"1998","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Warnock","year":"1998","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000087357","article-title":"Characteristic features of allergic airway inflammation in a murine model of infantile asthma","volume":"138","author":"Ohki","year":"2005","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/all.13985","article-title":"Mechanisms and therapeutic strategies for non-T2 asthma","volume":"75","author":"Sze","year":"2020","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.waojou.2020.100441","article-title":"Beliefs and Preferences Regarding Biological Treatments for Severe Asthma","volume":"13","author":"Bikov","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"g5517","DOI":"10.1136\/bmj.g5517","article-title":"Asthma: Pathogenesis and Novel Drugs for Treatment","volume":"349","author":"Olin","year":"2014","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jaip.2022.07.016","article-title":"Assessment of Real-World Escalation to Biologics in US Patients with Asthma","volume":"10","author":"Bender","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1111\/all.15089","article-title":"Advances and highlights in biomarkers of allergic diseases","volume":"76","author":"Ogulur","year":"2021","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12016-020-08776-8","article-title":"The Current State of Biologic Therapies for Treatment of Refractory Asthma","volume":"59","author":"Mavissakalian","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the Value of Mepolizumab for Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-017-0678-1","article-title":"Phenotype-Driven Therapeutics in Severe Asthma","volume":"17","author":"Opina","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1042\/CS20160487","article-title":"Cellular and molecular mechanisms of asthma and COPD","volume":"131","author":"Barnes","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e20221094","DOI":"10.1084\/jem.20221094","article-title":"T helper 2 cells in asthma","volume":"220","author":"Harker","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.0902185","article-title":"Importance of cytokines in murine allergic airway disease and human asthma","volume":"184","author":"Finkelman","year":"2010","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1146\/annurev.immunol.21.120601.140942","article-title":"Molecular mechanisms regulating th1 immune responses","volume":"21","author":"Szabo","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1084\/jem.182.5.1527","article-title":"Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and th2 cytokine expression in mice","volume":"182","author":"Gavett","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1084\/jem.190.9.1309","article-title":"T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production","volume":"190","author":"Cohn","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jaci.2017.08.020","article-title":"T(H)1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status","volume":"141","author":"Wisniewski","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"L71","DOI":"10.1152\/ajplung.00547.2017","article-title":"Th1 cytokines tnf-alpha and ifn-gamma promote corticosteroid resistance in developing human airway smooth muscle","volume":"316","author":"Britt","year":"2019","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.coi.2013.08.002","article-title":"Th17-mediated inflammation in asthma","volume":"25","author":"Newcomb","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1900068","DOI":"10.1183\/13993003.00068-2019","article-title":"Elevated serum IgE, oral corticosteroid dependence and IL-17\/22 expression in highly neutrophilic asthma","volume":"54","author":"Bullone","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eaao4747","DOI":"10.1126\/sciimmunol.aao4747","article-title":"Neutrophil cytoplasts induce T(H)17 differentiation and skew inflammation toward neutrophilia in severe asthma","volume":"3","author":"Krishnamoorthy","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1084\/jem.20061401","article-title":"Interleukin-17 is a negative regulator of established allergic asthma","volume":"203","author":"Togbe","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200801-086OC","article-title":"IL-23 and th17 cells enhance th2-cell-mediated eosinophilic airway inflammation in mice","volume":"178","author":"Wakashin","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/mi.2011.60","article-title":"Interleukin (IL)-4, IL-13, and IL-17a differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients","volume":"5","author":"Bellini","year":"2012","journal-title":"Mucosal Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mi.2012.76","article-title":"Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling","volume":"6","author":"Zhao","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.2684","article-title":"IL-17a produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction","volume":"18","author":"Kudo","year":"2012","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ni.1659","article-title":"Transforming growth factor-beta \u2018Reprograms\u2019 the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset","volume":"9","author":"Veldhoen","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-016-0600-2","article-title":"The transcription factor network in th9 cells","volume":"39","author":"Kaplan","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ni.1846","article-title":"Regulation of IL-9 expression by IL-25 signaling","volume":"11","author":"Angkasekwinai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00281-016-0601-1","article-title":"Th9 and other IL-9-producing cells in allergic asthma","volume":"39","author":"Koch","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.mucimm.2023.05.002","article-title":"Interleukin-9 promotes mast cell progenitor proliferation and CCR2-dependent mast cell migration in allergic airway inflammation","volume":"16","author":"Pajulas","year":"2023","journal-title":"Mucosal Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"Th9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMcibr1803610","article-title":"Epigenetic control of interleukin-9 in asthma","volume":"379","author":"Lloyd","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Parker, J.M., Oh, C.K., LaForce, C., Miller, S.D., Pearlman, D.S., Le, C., Robbie, G.J., White, W.I., White, B., and Molfino, N.A. (2011). Safety profile and clinical activity of multiple subcutaneous doses of medi-528, a humanized antiinterleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm. Med., 11.","DOI":"10.1186\/1471-2466-11-14"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-14-93","article-title":"A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma","volume":"14","author":"Oh","year":"2013","journal-title":"Respir. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.it.2012.10.003","article-title":"Drug targets in the cytokine universe for autoimmune disease","volume":"34","author":"Liu","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/cea.12138","article-title":"Perceived triggers of asthma: Key to symptom perception and management","volume":"43","author":"Janssens","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.15537\/smj.2018.2.20974","article-title":"Asthma prevalence among adults in Saudi Arabia","volume":"39","author":"Algazlan","year":"2018","journal-title":"Saudi Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5144\/0256-4947.2016.379","article-title":"Asthma and other allergic diseases among Saudi schoolchildren in Najran: The need for a comprehensive intervention program","volume":"36","author":"Alqahtani","year":"2016","journal-title":"Ann. Saudi Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cytogfr.2016.03.011","article-title":"T helper 2 and T follicular helper cells: Regulation and function of interleukin 4","volume":"30","author":"Sahoo","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramirez, G.A., Yacoub, M.R., Ripa, M., Mannina, D., Cariddi, A., Saporiti, N., Ciceri, F., Castagna, A., Colombo, G., and Dagna, L. (2018). Eosinophils from physiology to disease: A comprehensive review. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/9095275"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13223-023-00794-3","article-title":"Diagnostic value of IL-6 for patients with asthma: A meta-analysis","volume":"19","author":"Pan","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Heffler, E., Crimi, C., Maglio, A., Vatrella, A., Pelaia, G., and Canonica, G.W. (2022). Interleukins 4 and 13 in asthma: Key pathophysiologic cytokines and druggable molecular targets. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.851940"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mi.2016.47","article-title":"CD4+ Th2 cells are directly regulated by IL-10 during allergic airway inflammation","volume":"10","author":"Coomes","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00281-016-0605-x","article-title":"IL-9-producing cells in the development of IgE-mediated food allergy","volume":"39","author":"Shik","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"L843","DOI":"10.1152\/ajplung.00416.2018","article-title":"Regulation of IL-17A and implications for TGF-\u03b21 co modulation of airway smooth muscle remodeling in severe asthma","volume":"316","author":"Evasovic","year":"2019","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chan, B.C.L., Lam, C.W.K., Tam, L.S., and Wong, C.K. (2019). IL33: Roles in allergic inflammation and therapeutic perspectives. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00364"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s10753-014-9830-4","article-title":"IL-25 promotes Th2 immunity responses in airway inflammation of asthmatic mice via activation of dendritic cells","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1165\/rcmb.2016-0307TR","article-title":"Transforming growth factor \u03b21 function in airway remodelling and hyperresponsiveness. The missing link?","volume":"56","author":"Ojiaku","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/imcb.12522","article-title":"The onset, development, and pathogenesis of severe neutrophilic asthma","volume":"100","author":"Zhang","year":"2022","journal-title":"Immunol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Smolinska, S., Antol\u00edn-Am\u00e9rigo, D., Popescu, F.-D., and Jutel, M. (2023). Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612725"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200807-1126OC","article-title":"Severe exacerbations and decline in lung function in asthma","volume":"179","author":"Pedersen","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.rmed.2006.07.005","article-title":"Recent asthma exacerbations: A key predictor of future exacerbations","volume":"101","author":"Miller","year":"2007","journal-title":"Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/bmj.307.6910.982","article-title":"Respiratory viruses and exacerbations of asthma in adults","volume":"307","author":"Nicholson","year":"1993","journal-title":"BMJ"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1164\/ajrccm.154.3.8810601","article-title":"The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis","volume":"154","author":"Johnston","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaci.2005.11.034","article-title":"The September epidemic of asthma hospitalization: School children as disease vectors","volume":"117","author":"Johnston","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1503\/cmaj.091724","article-title":"Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza","volume":"182","author":"Barton","year":"2010","journal-title":"Can. Med Assoc. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0009922810368558","article-title":"Clinical features, risk factors, and complications among pediatric patients with pandemic influenza A (H1N1)","volume":"49","author":"Plessa","year":"2010","journal-title":"Clin. Pediatr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa0907673","article-title":"Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina","volume":"362","author":"Libster","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jaci.2013.06.006","article-title":"Viral infection of the lung: Host response and sequelae","volume":"132","author":"Yoo","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1183\/09031936.02.00254402","article-title":"Role of persistent infection in the control and severity of asthma: Focus on Chlamydia pneumoniae","volume":"19","author":"Von","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thx.2007.081752","article-title":"Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages","volume":"63","author":"Oliver","year":"2008","journal-title":"Thorax"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13562","DOI":"10.1073\/pnas.0804181105","article-title":"Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1\/2 cytokine and IL-10 production","volume":"105","author":"Message","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/thx.2004.037283","article-title":"Directly measured second hand smoke exposure and asthma health outcomes","volume":"60","author":"Eisner","year":"2005","journal-title":"Thorax"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1289\/ehp.11349","article-title":"A longitudinal study of indoor nitrogen dioxide levels and respiratory symptoms in inner-city children with asthma","volume":"116","author":"Hansel","year":"2008","journal-title":"Environ. Health Perspect."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.2010.135574","article-title":"A systematic review and meta-analysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)","volume":"67","author":"Petsky","year":"2012","journal-title":"Thorax"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(02)01047-1","article-title":"Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma","volume":"112","author":"Little","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_77","first-page":"118","article-title":"Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/all.15054","article-title":"Advances and highlights in asthma in 2021","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"220193","DOI":"10.1183\/16000617.0193-2022","article-title":"Cytokine-targeted therapies for asthma and COPD","volume":"32","author":"Schleich","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Henderson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): A prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/COPD.S80091","article-title":"AAirway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: Relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function","volume":"10","author":"Bafadhel","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/all.14514","article-title":"Asthma exacerbations on benralizumab are largely non-eosinophilic","volume":"76","author":"Poznanski","year":"2021","journal-title":"Allergy"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/all.14976","article-title":"Medical algorithms: Approach to adult asthma exacerbations","volume":"76","author":"Nair","year":"2021","journal-title":"Allergy"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: An update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1067\/mai.2003.1595","article-title":"Allergic and nonallergic forms of atopic diseases","volume":"112","author":"Novak","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.anai.2018.07.033","article-title":"Selecting the right biologic for your patients with severe asthma","volume":"121","author":"Manka","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"210144","DOI":"10.1183\/20734735.0144-2021","article-title":"A pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh","year":"2022","journal-title":"Breathe"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_92","first-page":"CD003559","article-title":"Omalizumab for Asthma in Adults and Children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin. Exp. Allergy"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1710-1492-7-9","article-title":"Long-term benefits of omalizumab in a patient with severe non-allergic asthma","volume":"7","author":"Menzella","year":"2011","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e011857","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: A UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kardas, G., Kuna, P., and Panek, M. (2020). Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01134"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/ACI.0000000000000284","article-title":"Biologic Therapy in the Management of Asthma","volume":"16","author":"McCracken","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of Omalizumab as Add-on Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled despite Best Available Therapy (Gina 2002 Step 4 Treatment): Innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaci.2014.09.034","article-title":"High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma","volume":"135","author":"Fowler","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.iac.2018.06.003","article-title":"Airway eosinophilopoietic and autoimmune mechanisms of eosinophilia in severe asthma","volume":"38","author":"Bhalla","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Sehmi","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13223-016-0174-5","article-title":"Airway autoimmune responses in severe eosinophilic asthma following low-dose mepolizumab therapy","volume":"13","author":"Mukherjee","year":"2017","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","article-title":"Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine","volume":"9","author":"Pavord","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1753465817717134","article-title":"Reslizumab in the Treatment of Inadequately Controlled Asthma in Adults and Adolescents with Elevated Blood Eosinophils: Clinical Trial Evidence and Future Prospects","volume":"11","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/JAA.S503048","article-title":"Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries from Central Eastern Europe and Baltics","volume":"18","author":"Mihaltan","year":"2025","journal-title":"J. Asthma Allergy"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/j.chest.2022.08.009","article-title":"Long-Term Real-World Effectiveness of Benralizumab in Patients with Severe Eosinophilic Asthma: Results from the Zephyr 2 Study","volume":"162","author":"Carstens","year":"2022","journal-title":"Chest"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Mepolizumab or Benralizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: Changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"17534666221107313","DOI":"10.1177\/17534666221107313","article-title":"Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: Evidence from randomized controlled trials and real-world studies","volume":"16","author":"Casale","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: Targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1753466620929231","DOI":"10.1177\/1753466620929231","article-title":"Switching from omalizumab to mepolizumab: Real-life experience from Southern Italy","volume":"14","author":"Carpagnano","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40265-024-02037-0","article-title":"Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan","volume":"84","author":"Lombardi","year":"2024","journal-title":"Drugs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jaip.2020.12.013","article-title":"Optimizing Omalizumab Dosing in Severe Asthma\u2014The Exploration of Therapeutic Drug Monitoring","volume":"9","author":"Kroes","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and Cerebrovascular Events among Patients Receiving Omalizumab: Results from Excels, a Prospective Cohort Study in Moderate to Severe Asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_133","unstructured":"CINQAIR (2025, June 01). Prescribing Information. Available online: https:\/\/www.cinqair.com\/globalassets\/cinqair\/prescribinginformation.pdf."},{"key":"ref_134","first-page":"564","article-title":"Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype","volume":"42","author":"Hom","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"ref_136","unstructured":"CTG Labs\u2014NCBI (2025, June 01). A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients with Eosinophilic Asthma, Available online: https:\/\/beta.clinicaltrials.gov\/study\/NCT01285323?tab=results#publications."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Calabrese, C., Vatrella, A., Busceti, M.T., Garofalo, E., Lombardo, N., Terracciano, R., and Pelaia, G. (2018). Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/4839230"},{"key":"ref_138","first-page":"CD010834","article-title":"Anti-IL5 therapies forasthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaip.2024.01.006","article-title":"Benralizumab in Eosinophilic Granulomatosis with Polyangiitis: Real-World Experience","volume":"12","author":"Nanzer","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in Severe Allergic Asthma Inadequately Controlled with Standard Therapy","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_141","unstructured":"CTG Labs\u2014NCBI (2025, June 01). A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 Mg\/Kg) as Treatment for Patients (12\u201375 Years of Age) with Eosinophilic Asthma, Available online: https:\/\/beta.clinicaltrials.gov\/study\/NCT01270464."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting 2-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an Anti-Interleukin-5 Receptor Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (Calima): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 in-flammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5\/5R Therapy in Severe Eosinophilic Asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab Treatment Results in Early and Sustained Improvements in Itch in Adolescents and Adults with Moderate to Severe Atopic Dermatitis: Analysis of the Randomized Phase 3 Studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"AB140","DOI":"10.1016\/j.jaad.2021.06.576","article-title":"Rapid and Sustained Improvement in Itch in Children Aged 6\u201311 Years with Severe Atopic Dermatitis (AD) Treated with Dupilumab: Analysis from the LIBERTY AD PEDS Phase 3 Trial","volume":"85","author":"Paller","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy\/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 SINUS-24 Study","volume":"143","author":"Han","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"AB199","DOI":"10.1016\/j.jaci.2022.12.622","article-title":"Dupilumab Improves Type 2 Comorbidity Outcomes in Patients with Eosinophilic Esophagitis and Comorbid Disease at Baseline: From Parts A and B of LIBERTY-EoE-TREET","volume":"151","author":"Spergel","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age","volume":"390","author":"Chehade","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: Implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-7961-10-8","article-title":"IL-3 and TNFa increase thymic stromal lymphopoietin receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation","volume":"10","author":"Cook","year":"2012","journal-title":"Clin. Mol. Allergy"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Gallelli, L., Terracciano, R., and Vatrella, A. (2021). Tezepelumab: A potential new biological therapy for severe refractory asthma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094369"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"key":"ref_161","unstructured":"(2025, June 02). Available online: https:\/\/www.fdanews.com\/articles\/188355-fda-awards-astrazeneca-and-amgens-tezepelumab-breakthrough-designation."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S198953","article-title":"Patient and physician preferences for attributes of biologic medications for severe asthma","volume":"13","author":"Gelhorn","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"SWIFT 1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","article-title":"The adherence and outcomes ben efits of using a connected, reusable auto-injector for self-injecting biologics: A narrative review","volume":"40","author":"Antalfy","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","article-title":"A portfolio of biologic self-injection devices in rheumatology: How patient involvement in device design can improve treatment experience","volume":"26","author":"Gettings","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2147\/PPA.S170636","article-title":"Com parison between prefilled syringe and autoinjector devices on patient-reported experiences and pharma cokinetics in galcanezumab studies","volume":"12","author":"Stauffer","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/PPA.S154181","article-title":"Preference for a prefilled syringe or an auto-injection device for de livering golimumab in patients with moderate-to-severe ulcerative colitis: A randomized crossover study","volume":"12","author":"Vermeire","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_169","first-page":"1061","article-title":"Subcu taneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: Patient preference and comparison of the self-injection experience","volume":"8","author":"Demary","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cpdd.726","article-title":"The pharmacokinetics and relative bioavailability of mepolizumab 100 mg liquid formu lation administered subcutaneously to healthy partici pants: A randomized trial","volume":"9","author":"Shabbir","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02770903.2019.1663428","article-title":"Comparison of au toinjector with accessorized prefilled syringe for benral izumab pharmacokinetic exposure: AMES trial results","volume":"58","author":"Martin","year":"2021","journal-title":"J Asthma"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ni.3370","article-title":"Interleukin 33 is a guardian of barriers and a local alarmin","volume":"17","author":"Martin","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.copbio.2014.09.001","article-title":"Enlarging the repertoire of therapeutic monoclonal antibodies platforms: Domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies","volume":"30","author":"Yang","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaci.2019.08.039","article-title":"IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation","volume":"144","author":"Allinne","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_179","unstructured":"Global Initiative for Asthma (GINA) (2025, June 01). Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2016\/01\/GINA_Report_2015_Aug11-1.pdf."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/COPD.S120445","article-title":"Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease","volume":"12","author":"Rhee","year":"2017","journal-title":"Int. J. Chronic Obstr. Pulmon. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): A multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_182","first-page":"2498","article-title":"Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"190","author":"Zhao","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind,placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A Phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, Phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cpt.803","article-title":"Dose-exposure\u2013response relationship of the investigational anti-IL-13 monoclonal antibody tralokinumab in patients with severe, uncontrolled asthma","volume":"103","author":"Baverel","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population","volume":"12","author":"Corren","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo controlled pivotal Phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.dmpk.2017.12.001","article-title":"A Randomized, Placebo-Controlled, Single Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tralokinumab in Japanese Healthy Volunteers","volume":"33","author":"Baverel","year":"2018","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/imt-2017-0191","article-title":"Tralokinumab for the Treatment of Severe, Uncontrolled Asthma: The ATMOSPHERE Clinical Development Program","volume":"10","author":"Panettieri","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for Severe, Uncontrolled Asthma (STRATOS 1 and STRATOS 2): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cea.12220","article-title":"The effects of lebrikizumab in patients with mild asthma following whole lungallergen challenge","volume":"44","author":"Scheerens","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma(LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e12176","DOI":"10.1002\/clt2.12176","article-title":"Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)","volume":"12","author":"Szefler","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI\u2014A study: Initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"240088","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: A state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur. Respir. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:40Z","timestamp":1760033260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":199,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18071021"],"URL":"https:\/\/doi.org\/10.3390\/ph18071021","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}